Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Dr. Reddy's price target raised to $53 from $45 at Barclays » 06:39
07/30/20
07/30
06:39
07/30/20
06:39
RDY

Dr. Reddy's

$58.71 /

+4.18 (+7.67%)

Barclays analyst Balaji…

Barclays analyst Balaji Prasad raised the firm's price target on Dr. Reddy's to $53 from $45 and keeps an Equal Weight rating on the shares following the company's fiscal Q1 results. The company continues to execute well on its strategy of broadening its product portfolio across geographies, Prasad tells investors in a research note.

ShowHide Related Items >><<
RDY Dr. Reddy's
$58.71 /

+4.18 (+7.67%)

RDY Dr. Reddy's
$58.71 /

+4.18 (+7.67%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
RDY Dr. Reddy's
$58.71 /

+4.18 (+7.67%)

RDY Dr. Reddy's
$58.71 /

+4.18 (+7.67%)

Over a week ago
Hot Stocks
Amarin announces data from REDUCE-IT REVASC analysis of VASCEPA » 07:15
07/27/20
07/27
07:15
07/27/20
07:15
AMRN

Amarin

$6.51 /

-0.065 (-0.99%)

Amarin Corporation…

Amarin Corporation announced that data from the REDUCE-IT REVASC analysis, presented as an encore by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD Prevention, showed that administration of 4 g/day of VASCEPA resulted in a significant 34% reduction in first coronary revascularizations versus placebo. Similar reductions of 36% were observed in total, or first and subsequent, revascularizations. In newly presented data, an early coronary revascularization benefit signal was shown in a prespecified exploratory analysis, with sustained statistical significance attained by 11 months. Coronary revascularization procedures, such as stenting and coronary artery bypass grafts, are invasive, carry multiple risks, and can have significant direct and indirect costs. Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. These procedures, whether pre-scheduled or performed in an emergency, inevitably result in additional time spent in a healthcare setting. The analyses from the REDUCE-IT trial included several types of coronary revascularization in statin-treated patients with persistently elevated triglycerides, who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including elective, urgent, and emergent revascularizations, which were reduced by 32%, 34%, and 38%, respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention by 32% and CABG by 39% relative to placebo/ REDUCE-IT was not specifically powered to examine individual cardiovascular endpoints, therefore p-values presented for these revascularization analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, coronary revascularization as an endpoint can sometimes be considered subjective; however, these endpoints were adjudicated by an independent, blinded clinical endpoint committee. Results from the total coronary revascularization events analyses are consistent across the various recurrent event statistical models and are also consistent with the first coronary revascularization events results. Together, the REDUCE-IT first and total coronary revascularization events results support the robustness and consistency of the clinical benefit of VASCEPA therapy in reducing coronary revascularization. Funding from Amarin was provided to Brigham and Women's Hospital for Dr. Deepak L. Bhatt's work as the REDUCE-IT study chair and global principal investigator.

ShowHide Related Items >><<
AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

AMRN Amarin
$6.51 /

-0.065 (-0.99%)

Hot Stocks
Dr. Reddy's receives FDA approval for Xeglyze for lice » 15:56
07/24/20
07/24
15:56
07/24/20
15:56
RDY

Dr. Reddy's

$53.87 /

-0.58 (-1.07%)

Xeglyze is a pediculicide…

Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older, according to a post to the FDA website. Reference Link

ShowHide Related Items >><<
RDY Dr. Reddy's
$53.87 /

-0.58 (-1.07%)

RDY Dr. Reddy's
$53.87 /

-0.58 (-1.07%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
RDY Dr. Reddy's
$53.87 /

-0.58 (-1.07%)

RDY Dr. Reddy's
$53.87 /

-0.58 (-1.07%)

Hot Stocks
CADTH committee recommends reimbursement for Amarin's Vascepa » 16:01
07/20/20
07/20
16:01
07/20/20
16:01
AMRN

Amarin

$6.59 /

-0.105 (-1.57%)

The CADTH Canadian Drug…

The CADTH Canadian Drug Expert Committee recommends that icosapent ethyl be reimbursed to reduce the risk of CV events in statin-treated patients with elevated triglycerides, if certain conditions are met, according to a final recommendation document posted to the CADTH site. Icosapent ethyl is marketed under the brand name Vascepa. Reference Link

ShowHide Related Items >><<
AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

AMRN Amarin
$6.59 /

-0.105 (-1.57%)

Hot Stocks
Dr. Reddy's announces launch of OTC Nicotine Polacrilex Lozenges in U.S. market » 05:26
07/14/20
07/14
05:26
07/14/20
05:26
RDY

Dr. Reddy's

$51.55 /

-0.22 (-0.42%)

Dr. Reddy's…

Dr. Reddy's Laboratories announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette Lozenges in the U.S. market. Dr. Reddy's Nicotine Polacrilex Lozenges are available in multiple pack sizes based on consumers' requirements.

ShowHide Related Items >><<
RDY Dr. Reddy's
$51.55 /

-0.22 (-0.42%)

RDY Dr. Reddy's
$51.55 /

-0.22 (-0.42%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
RDY Dr. Reddy's
$51.55 /

-0.22 (-0.42%)

RDY Dr. Reddy's
$51.55 /

-0.22 (-0.42%)

Over a month ago
Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 10:43
06/29/20
06/29
10:43
06/29/20
10:43
AMRN

Amarin

$6.67 /

-0.025 (-0.37%)

Pharmaceuticals Analysts,…

Pharmaceuticals Analysts, along with Zachary Silbersher, the founding partner of Kroub, Silbersher & Kolmykov (KSK), PLLC, discuss the likelihood that Amarin will win its appeal for Vascepa on an Analyst/Industry conference call to be held on June 29 at 11 am.

ShowHide Related Items >><<
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

  • 19
    Jul
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

Frequency Therapeutics

$22.68 /

-0.47 (-2.03%)

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

Options
Notable open interest changes for June 23rd » 08:55
06/23/20
06/23
08:55
06/23/20
08:55
AAPL

Apple

$359.08 /

+9.53 (+2.73%)

, AMRN

Amarin

$7.13 /

+0.22 (+3.18%)

, BAC

Bank of America

$24.62 /

-0.34 (-1.36%)

, AAL

American Airlines

$14.91 /

-1.085 (-6.78%)

Monday's total…

Monday's total option volume of 25.5 million contracts resulted in net open interest growth of 4.84 million calls and 3.73 million puts. Apple (AAPL), Amarin (AMRN), Bank of America (BAC) and American Airlines (AAL) saw the greatest growth. Top five new positions opened include 51k Ford (F) Aug-20 6 puts, 27k Amarin (AMRN) Sep-20 7 calls, 22k Amarin (AMRN) Sep-20 10 calls, 20k Amarin (AMRN) Sep-20 6 puts and 20k US Steel (X) Aug-20 7 puts.

ShowHide Related Items >><<
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

06/23/20 Credit Suisse
Apple launches at WWDC more incremental than thesis-changing, says Credit Suisse
06/23/20 Oppenheimer
Apple creating 'wide moat' for own ecosystem, says Oppenheimer
06/23/20 Goldman Sachs
Apple's revamped Mac rollout plans look aggressive, says Goldman Sachs
AMRN Amarin
$7.13 /

+0.22 (+3.18%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

06/11/20 BTIG
First Department ruling 'a significant positive' for Ambac Financial, says BTIG
06/05/20 Wells Fargo
Bank of America price target raised to $35 from $30 at Wells Fargo
04/16/20 DA Davidson
Bank of America price target raised to $26 from $24 at DA Davidson
04/16/20 BMO Capital
Bank of America price target lowered to $24 from $26 at BMO Capital
AAL American Airlines
$14.91 /

-1.085 (-6.78%)

06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

  • 23
    Jun
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

Options
Unusual call flow in option market yesterday » 07:35
06/23/20
06/23
07:35
06/23/20
07:35
X

U.S. Steel

$8.05 /

-0.06 (-0.74%)

, AMRN

Amarin

$7.13 /

+0.22 (+3.18%)

Notable call activity was…

Notable call activity was cited Monday in US Steel (X) and Amarin (AMRN).

ShowHide Related Items >><<
X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

06/09/20 GLJ Research
U.S. Steel upgraded to Hold from Sell at GLJ Research
03/23/20 BMO Capital
U.S. Steel price target lowered to $6 from $9 at BMO Capital
01/31/20 BMO Capital
U.S. Steel price target lowered to $10 from $14 at BMO Capital
01/14/20 Goldman Sachs
U.S. Steel reinstated with a Sell at Goldman Sachs
AMRN Amarin
$7.13 /

+0.22 (+3.18%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

Options
Double spread collar in Amarin opens bullish position » 12:00
06/22/20
06/22
12:00
06/22/20
12:00
AMRN

Amarin

$6.82 /

-0.095 (-1.37%)

Double spread collar in…

Double spread collar in Amarin opens bullish position. Shares little changed this morning near $6.80 with a 4-way spread on the ISE where a customer appears to have sold the Sep 5/6 put spread to buy the Sep 7/10 call spread a total of 20k times, opening on all legs. For the largest tranche of 15k, the net credit on the put spread was 27c and the debit on the call spread 77c, for a net debit of 50c, or about $1M on the package. Net delta on the package is nearly 670k shares, or 9% the average daily turnover in the name. Amarin shares dropped nearly 70% from over $13 to $4 on March 31 related to a court ruling. Today's trade could return a 500% gain to the buyer if shares were to return to double digit territory over the next three months.

ShowHide Related Items >><<
AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.